Precision Care in the Treatment of Pediatric Asthma

Overview

Journal Curr Opin Pediatr

Specialty Pediatrics

Date 2024 Feb 27

PMID 38411592

Authors

Lina Mahmood

Sevdenur Keskin

Akilah A Jefferson

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Precision medicine in pediatric asthma involves identification of asthma phenotypes, genetic markers, biomarkers, and biologics that target specific pathways. This review includes a discussion of the efficacy of currently approved biologics for pediatric asthma and most recent advances in biomarker/phenotype identification and genetic associations that affect asthma care.

Recent Findings: Biologics targeting type-2 mediated pathways have shown success in the treatment of moderate to severe asthma in pediatric and adult patients. In comparative studies, dupilumab, an interleukin-4 (IL-4) alpha receptor inhibitor, and mepolizumab, an IL-5 inhibitor, have shown more improvement in asthma exacerbation rates and lung function compared to other biologics such as tezepelumab, omalizumab and benralizumab. Other methods used to categorize asthma treatment response have been investigated and include use of biomarkers such as fractional exhaled nitric oxide (FeNO). Genomic studies are also emerging in precision care for pediatric asthma.

Summary: An understanding of underlying immunologic and genetic mechanisms affecting the development of asthma in pediatric patients has resulted in the production of numerous targeted therapies that have led to improvement in lung function and reduced exacerbation burden.

Citing Articles

Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.

Indolfi C, Klain A, Capuano M, Colosimo S, Rapillo R, Miraglia Del Giudice M Children (Basel). 2025; 12(2).

PMID: 40003269 PMC: 11854818. DOI: 10.3390/children12020167.

References

Turner M, DaSilva-Arnold S, Luo N, Hu X, West C, Sun L . STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis. Invest Ophthalmol Vis Sci. 2014; 55(6):3803-8. PMC: 4062401. DOI: 10.1167/iovs.13-13685. View

Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist A, Colice G . DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020; 21(1):279. PMC: 7576983. DOI: 10.1186/s12931-020-01541-7. View

Jackson D, Bacharier L, Phipatanakul W, Sher L, Domingo C, Papadopoulos N . Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2023; 131(1):44-51.e4. DOI: 10.1016/j.anai.2023.03.014. View

Menzies-Gow A, Wechsler M, Brightling C, Korn S, Corren J, Israel E . Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023; 11(5):425-438. DOI: 10.1016/S2213-2600(22)00492-1. View

Asher M, Rutter C, Bissell K, Chiang C, El Sony A, Ellwood E . Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021; 398(10311):1569-1580. PMC: 8573635. DOI: 10.1016/S0140-6736(21)01450-1. View

Di Cicco M, Peroni D, Ragazzo V, Comberiati P . Application of exhaled nitric oxide (FeNO) in pediatric asthma. Curr Opin Allergy Clin Immunol. 2021; 21(2):151-158. DOI: 10.1097/ACI.0000000000000726. View

Su M, Lin W, Tsai C, Chiang B, Yang Y, Lin Y . Childhood asthma clusters reveal neutrophil-predominant phenotype with distinct gene expression. Allergy. 2018; 73(10):2024-2032. DOI: 10.1111/all.13439. View

Rastogi D . Pediatric obesity-related asthma: A prototype of pediatric severe non-T2 asthma. Pediatr Pulmonol. 2020; 55(3):809-817. PMC: 7694442. DOI: 10.1002/ppul.24600. View

Gupta A, Pouliquen I, Austin D, Price R, Kempsford R, Steinfeld J . Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019; 54(12):1957-1967. PMC: 6972599. DOI: 10.1002/ppul.24508. View

10.

Burton B, Britton G, Fang H, Verhagen J, Ben Smithers , Sabatos-Peyton C . Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014; 5:4741. PMC: 4167604. DOI: 10.1038/ncomms5741. View

11.

Gonzalez-Uribe V, Romero-Tapia S, Castro-Rodriguez J . Asthma Phenotypes in the Era of Personalized Medicine. J Clin Med. 2023; 12(19). PMC: 10573947. DOI: 10.3390/jcm12196207. View

12.

Brusselle G, Quirce S, Papi A, Kuna P, Chipps B, Hanania N . Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma. J Allergy Clin Immunol Pract. 2022; 11(3):873-884.e11. DOI: 10.1016/j.jaip.2022.11.044. View

13.

Gans M, Gavrilova T . Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatr Respir Rev. 2019; 36:118-127. DOI: 10.1016/j.prrv.2019.08.002. View

14.

Nopsopon T, Lassiter G, Chen M, Alexander G, Keet C, Hong H . Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022; 151(3):747-755. PMC: 9992307. DOI: 10.1016/j.jaci.2022.11.021. View

15.

Pavord I, Deniz Y, Corren J, Casale T, FitzGerald J, Izuhara K . Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2022; 11(4):1213-1220.e2. DOI: 10.1016/j.jaip.2022.11.043. View

16.

Fiocchi A, Phipatanakul W, Zeiger R, Durrani S, Cole J, Msihid J . Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023; 62(5). PMC: 10620476. DOI: 10.1183/13993003.00558-2023. View

17.

Pakkasela J, Ilmarinen P, Honkamaki J, Tuomisto L, Andersen H, Piirila P . Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. 2020; 20(1):9. PMC: 6954552. DOI: 10.1186/s12890-019-1040-2. View

18.

Raedler D, Ballenberger N, Klucker E, Bock A, Otto R, Prazeres da Costa O . Identification of novel immune phenotypes for allergic and nonallergic childhood asthma. J Allergy Clin Immunol. 2014; 135(1):81-91. DOI: 10.1016/j.jaci.2014.07.046. View

19.

Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W . Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol. 2010; 184(4):2194-203. DOI: 10.4049/jimmunol.0901379. View

20.

Cloutier M, Baptist A, Blake K, Brooks E, Bryant-Stephens T, DiMango E . 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020; 146(6):1217-1270. PMC: 7924476. DOI: 10.1016/j.jaci.2020.10.003. View